Standout Papers

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors ... 2018 2026 2020 2023 493
  1. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer (2018)
    Thanyanan Reungwetwattana, Kazuhiko Nakagawa et al. Journal of Clinical Oncology
  2. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3) (2018)
    Yi‐Long Wu, Myung‐Ju Ahn et al. Journal of Clinical Oncology

Immediate Impact

8 by Nobel laureates 16 from Science/Nature 64 standout
Sub-graph 1 of 21

Citing Papers

De novo design of allosterically switchable protein assemblies
2024 StandoutNatureNobel
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
2023 Standout
1 intermediate paper

Works of Andy Brown being referenced

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
2018 Standout
A nano-disperse ferritin-core mimetic that efficiently corrects anemia without luminal iron redox activity
2014

Author Peers

Author Last Decade Papers Cites
Andy Brown 2727 1440 242 1849 246 8.3k
Zhen Fan 2165 2399 133 590 252 9.2k
Masatoshi Hasegawa 2537 839 38 1846 295 9.1k
Wen‐Hua Zhang 2952 1285 102 332 380 9.7k
Robert W. Thompson 2236 698 18 1213 189 9.4k
Li Ren 2136 3212 445 848 654 14.9k
Ke Yang 2011 968 41 400 336 7.9k
J. David Robertson 5013 2413 177 621 243 13.8k
Yang Liu 2806 1710 159 440 510 7.4k
Minoru Suzuki 2260 630 66 1385 466 8.4k
Olivier Tillement 3400 3334 110 1678 261 8.3k

All Works

Loading papers...

Rankless by CCL
2026